These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Developments in outpatient parenteral antimicrobial therapy (OPAT) for Gram-positive infections in Europe, and the potential impact of daptomycin. Nathwani D J Antimicrob Chemother; 2009 Sep; 64(3):447-53. PubMed ID: 19584105 [TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of daptomycin in outpatient parenteral antimicrobial therapy: a prospective and multicenter cohort study (DAPTODOM trial). Cervera C; Sanroma P; González-Ramallo V; García de la María C; Sanclemente G; Sopena N; Pajarón M; Segado A; Mirón M; Antón F; Basterretxea A; Cuende A; Miró JM; Infect Dis (Lond); 2017 Mar; 49(3):200-207. PubMed ID: 27820968 [TBL] [Abstract][Full Text] [Related]
4. [Daptomycin in the treatment of Gram-positive infections in patients with chronic renal failure]. Sarriá Cepeda C Enferm Infecc Microbiol Clin; 2012 Feb; 30 Suppl 1():38-42. PubMed ID: 22541974 [TBL] [Abstract][Full Text] [Related]
5. Daptomycin. Enoch DA; Bygott JM; Daly ML; Karas JA J Infect; 2007 Sep; 55(3):205-13. PubMed ID: 17629567 [TBL] [Abstract][Full Text] [Related]
6. Daptomycin for outpatient parenteral antibiotic therapy: a European registry experience. Seaton RA; Gonzalez-Ramallo VJ; Prisco V; Marcano-Lozada M; Gonzalez-Ruiz A; Gallegos B; Menichetti F; Loeffler J; Bouylout K; Chaves RL Int J Antimicrob Agents; 2013 May; 41(5):468-72. PubMed ID: 23473943 [TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria. Rybak MJ Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():24-32. PubMed ID: 16445721 [TBL] [Abstract][Full Text] [Related]
8. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria. Katz DE; Lindfield KC; Steenbergen JN; Benziger DP; Blackerby KJ; Knapp AG; Martone WJ Int J Clin Pract; 2008 Sep; 62(9):1455-64. PubMed ID: 18662172 [TBL] [Abstract][Full Text] [Related]
14. Daptomycin in the treatment of skin, soft-tissue and invasive infections due to Gram-positive bacteria. Johnson A Future Microbiol; 2006 Oct; 1(3):255-65. PubMed ID: 17661638 [TBL] [Abstract][Full Text] [Related]
15. Daptomycin: first in a new class of antibiotics for complicated skin and soft-tissue infections. Kern WV Int J Clin Pract; 2006 Mar; 60(3):370-8. PubMed ID: 16494659 [TBL] [Abstract][Full Text] [Related]
16. [Daptomycin in home hospitalization]. González Ramallo VJ Med Clin (Barc); 2010 Dec; 135 Suppl 3():48-54. PubMed ID: 21477704 [TBL] [Abstract][Full Text] [Related]
17. [Daptomycin--a new antibiotic for the treatment of skin and soft tissue infections]. Mathiesen L; Midtvedt T; Solberg CO Tidsskr Nor Laegeforen; 2006 Sep; 126(18):2383-4. PubMed ID: 16998552 [TBL] [Abstract][Full Text] [Related]
18. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Carpenter CF; Chambers HF Clin Infect Dis; 2004 Apr; 38(7):994-1000. PubMed ID: 15034832 [TBL] [Abstract][Full Text] [Related]
19. Clinical utility of daptomycin in infective endocarditis caused by Gram-positive cocci. Cervera C; Castañeda X; Pericas JM; Del Río A; de la Maria CG; Mestres C; Falces C; Marco F; Moreno A; Miró JM Int J Antimicrob Agents; 2011 Nov; 38(5):365-70. PubMed ID: 21420835 [TBL] [Abstract][Full Text] [Related]